NasdaqGM - Nasdaq Real Time Price USD

Protagonist Therapeutics, Inc. (PTGX)

44.41
+0.64
+(1.46%)
At close: May 15 at 4:00:00 PM EDT
42.01
-2.40
(-5.40%)
Pre-Market: 4:01:25 AM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for PTGX

Recent News: PTGX

View More
Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain

Protagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term Gain
Insider Monkey 6 days ago

Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting
ACCESS Newswire 6 days ago
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Simply Wall St. 7 days ago
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates

Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
Zacks 9 days ago

Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update
ACCESS Newswire 9 days ago

Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025
ACCESS Newswire 22 days ago

Protagonist Therapeutics Reports Granting of Inducement Award
ACCESS Newswire 29 days ago

Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill
ACCESS Newswire last month
Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?

Wall Street Analysts See a 27.36% Upside in Protagonist Therapeutics (PTGX): Can the Stock Really Move This High?
Zacks last month
Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025?

Analysts Mentions Growth Catalysts for Protagonist Therapeutics (PTGX) — Best Biotech Stock for 2025?
Insider Monkey last month

Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
ACCESS Newswire last month
View More

Related Tickers

MLTX MoonLake Immunotherapeutics
37.66
+1.81%
 
CRNX Crinetics Pharmaceuticals, Inc.
31.21
-0.26%
 
RYTM Rhythm Pharmaceuticals, Inc.
60.18
+5.06%
 
SRRK Scholar Rock Holding Corporation
30.83
+0.95%
 
AKRO Akero Therapeutics, Inc.
39.96
+5.49%
 
CYTK Cytokinetics, Incorporated
29.84
-0.53%
 
IDYA IDEAYA Biosciences, Inc.
17.31
+1.23%
 
BBIO BridgeBio Pharma, Inc.
33.74
+0.24%
 
KYMR Kymera Therapeutics, Inc.
30.02
+0.91%
 
ACLX Arcellx, Inc.
58.45
-0.97%